Suppr超能文献

血清对细菌丙酮酸脱氢酶的反应性:提高抗线粒体抗体对原发性胆汁性肝硬化诊断的特异性。

Serum reactivity against bacterial pyruvate dehydrogenase: increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis.

作者信息

Miyakawa Hiroshi, Tanaka Atsushi, Selmi Carlo, Hosoya Naomi, Mataki Norikazu, Kikuchi Kentaro, Kato Takashi, Arai Junya, Goto Toshihiro, Gershwin M Eric

机构信息

Fourth Department of Internal Medicine, Teikyo University School of Medicine, Kanagawa 213-8507, Japan.

出版信息

Clin Dev Immunol. 2006 Jun-Dec;13(2-4):289-94. doi: 10.1080/17402520600668706.

Abstract

Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity can be found in non-PBC sera when lower dilutions are used, thus raising issues about the specificity and sensitivity of the test. AMA reacts primarily with the lipoylated domains of pyruvate dehydrogenase-E2 (PDC-E2) which is highly conserved across species, including bacteria. We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53 controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-E2 using immunoblotting (IB). A murine anti-human PDC-E2 monoclonal antibody (mAB) was used as control. We further studied positive sera using adsorption with a synthetic E. coli peptide sharing similarity with human PDC-E2. Finally, we verified whether a unique buffer for E. coli preparation could reduce non-specific serum reactivity. Results demonstrated that 100% of anti-PDC-E2-positive PBC and up to 38% of control sera at 1:10 dilution recognized E. coli PDC-E2 at IB while dilution tests indicated that the overall potency of PBC reactivity was 100-fold higher compared to controls. In fact, a subgroup (20-38%) of non-PBC sera were positive at low titers but lost the reactivity when absorbed with the synthetic E. coli peptide. Finally, our unique buffer reduced the reactivity of non-PBC sera as measured by ELISA. In conclusion, we demonstrated that weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions and that such reactivity is not due to AMA-positivity. The use of a specific buffer might avoid the risk of false positive AMA determinations when E. coli-expressed recombinant antigens are used.

摘要

抗线粒体抗体(AMA)是原发性胆汁性肝硬化(PBC)的血清标志物。然而,当使用较低稀释度时,非PBC血清中也可检测到AMA阳性,这就引发了关于该检测特异性和敏感性的问题。AMA主要与丙酮酸脱氢酶-E2(PDC-E2)的脂酰化结构域发生反应,该结构域在包括细菌在内的所有物种中都高度保守。我们使用免疫印迹法(IB),研究了77份血清样本,其中包括24份抗PDC-E2阳性PBC患者的血清样本以及53份对照样本(16份自身免疫性肝炎(AIH)患者的血清样本、10份原发性硬化性胆管炎(PSC)患者的血清样本和27份健康个体的血清样本)在系列稀释度(1:10、1:20和1:40)下对过表达人PDC-E2的大肠杆菌DH5α裂解物的反应性。使用鼠抗人PDC-E2单克隆抗体(mAB)作为对照。我们进一步使用与人PDC-E2具有相似性的合成大肠杆菌肽进行吸附,研究阳性血清样本。最后,我们验证了一种用于制备大肠杆菌的独特缓冲液是否可以降低非特异性血清反应性。结果表明,在免疫印迹法中,100%的抗PDC-E2阳性PBC血清样本以及高达38%的1:10稀释度对照血清样本可识别大肠杆菌PDC-E2,而稀释试验表明,PBC反应性的总体效力比对照高100倍。事实上,一部分(20-38%)非PBC血清样本在低滴度时呈阳性,但在用合成大肠杆菌肽吸附后失去反应性。最后,我们的独特缓冲液降低了通过酶联免疫吸附测定法(ELISA)检测到的非PBC血清的反应性。总之,我们证明了非PBC血清在较低稀释度下与大肠杆菌PDC-E2存在弱交叉反应,且这种反应性并非由AMA阳性所致。当使用大肠杆菌表达的重组抗原时,使用特定缓冲液可能避免AMA测定出现假阳性的风险。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验